@fireflyann

volunteer #CRCSM librarian #BRAF & #NRAS FB grps Stage 4 CRC Support & Colon Cancer Stars trials Stage 2/3 pts https://xitter.cf/t.co/48vU5493pH

 Bay Area, California
facebook.com/groups/208490666601307/
Joined June 2009
  • Tweets22.8K
  • Following3.3K
  • Followers1.6K
2.4KMedia
Started a BRAF Colorectal Cancer Public Library group on Facebook. So many significant trials, research findings, changes to NCCN guidelines, etc. in the last 2 years. Gathering high level research/interviews into 1 place seems wise and useful. #BRAFCRC facebook.com/groups/20849066…
4
12
2
65
Cancer vaccines are being explored not only to help prevent cancer from returning, but also to prevent it from developing. At #ESMO26, Dr. Eduardo Vilar-Sanchez will present research on a vaccine designed for people with Lynch syndrome, an inherited condition that raises the risk of several cancers. Read more about the future of cancer vaccine research: spr.ly/6013BHbPEZ @evilarsan #EndCancer

Melanoma Vaccine Ushers in New Hope for Cancer Patients (Gift Article)

Beyond melanoma, scientists are studying cancer vaccines for glioblastoma, pancreatic cancer and more.

nytimes.com
1
3
2
36
3,064
Kevan Shokat (@kevansf) made KRAS druggable. With daraxonrasib now in the clinic, he is “all in” on the ultimate target: p53 Shokat was named 2026 Stephenson Global Prize winner cancerletter.com/conversatio…
8
46
10
268
58,212
iKRAS #Daraxonrasib in pretreated #PDAC at @myESMO #ESMO26 ‼️Subgroup analysis (careful with statistical power) 👉PFS benefit for G12D, G12V and G12R 👉OS benefit for all but challenging due to small numbers 👉ORR varies #ESMOAmbassadors
1
3
10
663
Today at #ESMO26: Zev Wainberg will present additional subgroup analyses from the phase 3 RASolute 302 study of daraxonrasib vs. chemotherapy in previously treated metastatic pancreatic adenocarcinoma. @MSKCancerCenter's @EileenMOReilly is the senior author. 📅 October 23 | 2:22 p.m. CEST
A promotional graphic featuring headshots of Zev Wainberg and Eileen O'Reilly and the presentation title and date.

ALT A promotional graphic featuring headshots of Zev Wainberg and Eileen O'Reilly and the presentation title and date.

1
3
14
542
Coming up at #ESMO26: MSK gastrointestinal medical oncologist @EileenMOReilly will present the AMPLIFY-7P randomized phase 2 study comparing an mKRAS-specific immunotherapy with observation in patients with resected pancreatic ductal adenocarcinoma. 🗓️ Friday, October 23 | 2:32 p.m. CEST
11
1
24
2,270
Tango reports 82% tumor response rate in trial of combo therapy (Daraxonrasib plus vopimetostat) for advanced #PancreaticCancer at #ESMO26 statnews.com/2026/10/23/esmo… Reduced toxicity data is particularly important as a lower Daraxonrasib dose can be used.

Tango reports 82% tumor response rate in trial of combo therapy for advanced pancreatic cancer

An experimental drug combination led to tumor responses in 82% of patients with a certain type of advanced pancreatic cancer, Tango Therapeutics reported.

statnews.com
3
52
5
137
13,095
📌 806P: Extended ctDNA sequencing to optimize patient selection for anti-EGFR re-treatment vs. alternative late-line therapies in RAS/BRAF wild-type metastatic colorectal cancer (PARERE and CITRIC trials) 📍 Poster Area - Hall 5 🗓️ Sunday, October 25th 🕒 12:00 – 12:45 #ESMO26
8
10
488
🧬 NICHE-2 | Phase II | dMMR colon cancer 🇳🇱 👥 111 pts | Nivo + ipi → surgery 🎯 3-y DFS 100% 📈 5-y OS 100% 🩸 ctDNA clearance 82% pre-op ✅ All ctDNA− post-op ⚠️ Single-arm trial 💡 Remarkable long-term outcomes! 🔗 doi.org/10.1016/S0140-6736(2… @OncoAlert
4
31
3
72
7,829
Published today @TheLancet NICHE-2: 4 weeks of immunotherapy + surgery ➡️ 100% 3-year DFS and 100% 5-year OS in dMMR colon cancer. Congratulations to @MyriamChalabi et al ⭐️ Pleased to author the editorial commentary with @jonathanloree on these remarkable results and potential Implications of what comes next. doi.org/10.1016/S0140-6736(2… @BCCancer
15
25
1,550
Lesser known result of NICHE2 #ESMO22 study showed signs of an increased response for Lynch Syndrome pts (78% pCR vs 58% pCR). @_GeorgiaHurst @lynchsyndrome @CCAREfightlynch @LynchSyndromeUK @AliveAndKicknDD @JRushFoundation @DFarberYoungCRC @MattYurgelun @HHampel1
Smitha Krishnamurthi@smitha4211 Sep 2022
Congratulations @MyriamChalabi and colleagues on NICHE 2! Stunning waterfall plot. Interesting that pCR was higher in patients with Lynch Syndrome #ESMO22
1
4
11
NICHE-2 | Four Weeks of Immunotherapy. Remarkable Results. Part 1: Why dMMR colon cancer? Part 2: Nivolumab + ipilimumab before surgery. Part 3: 98% pathological response | 95% MPR | 68% pCR | 100% 3-year DFS. Part 4: ctDNA clearance, organ preservation and unanswered questions. Take-home: Short-course neoadjuvant immunotherapy shows exceptional promise, but surgery omission remains unproven. References: NEJM 2024; ESMO 2024 LBA24. #NICHE2 #dMMR #ColonCancer #Immunotherapy #ctDNA #GIOncology #MVOnco
1
9
28
1,707
Replying to @OpenMedKate @DrShubhamPant @GIcancerDoc
Shared this great Patient Handout for Daraxonrasib in our FB group.
1
8
8
480
“Chemo brain” is one of the most common things my patients ask me about. We still have no proven drug to treat it. In our small phase II trial, breast cancer survivors with cognitive complaints took oxaloacetate for 8 weeks. Every participant who completed the study reported improvement in cognition, along with less fatigue and better physical function. It’s an early signal, not an answer. A randomized, placebo-controlled trial is the next step. Led by Dr. Patti Ganz, with thanks to @BCRFcure. Out now in @JCOOA_ASCO. doi.org/10.1200/OA-26-00063 #bcsm
2
14
31
1,478
Replying to @OpenMedKate @DrShubhamPant @GIcancerDoc
Great Patient Handout info! Kudos to the medication lists from @DrDanielKing
1
3
1
6
812
🚨: The @FDA has granted accelerated approval to the immunotherapy Jemperli (dostarlimab) for adults with stage 2 or 3 rectal cancer whose tumors have specific genetic characteristics known as mismatch repair-deficient (MMRd) or microsatellite instability-high (MSI-H). The approach, developed at MSK by gastrointestinal medical oncologists Dr. Andrea Cercek (@AndreaCercek) and Dr. Luis Diaz Jr. (@ldiaz1971), uses immunotherapy alone to harness the body’s own immune system to fight cancer. This allows some patients to skip standard treatment for rectal cancer, which includes surgery, radiation, and chemotherapy, and can have life-altering consequences for bowel and urinary function, as well as fertility. Learn more: bit.ly/4zEQoil
6
27
3
123
9,728
🚨 FDA approval for dostarlimab in locally advanced dMMR/MSI-H rectal cancer! This was based on AZUR-1, with full data coming at @myESMO. #ESMO26 No recurrences among responders after more than 2 years of median follow-up! We know immunotherapy works, and when patients respond, those responses can be incredible. I’ve been using immunotherapy with curative intent in these patients, and I haven’t been disappointed. The fact that we’re potentially curing solid tumors with systemic therapy alone, without chemotherapy, radiation, or surgery, is magical. Looking forward to the full data and seeing this approach become more broadly available to patients. @OncoAlert @Onco_Nexus @TheGutOncLab fda.gov/news-events/press-an…

FDA Approves Immunotherapy That May Allow Certain Patients with Rectal Cancer to Avoid Chemothera...

The U.S. Food and Drug Administration today granted accelerated approval for a new use of the immunotherapy Jemperli (dostarlimab-gxly) that may allow some patients with locally advanced rectal...

fda.gov
2
25
3
61
3,722
Expansion: from 294 to 344 patients new arm for Colorectal Cancer Patients: Part B1 w JAB-23E73 combined with cetuximab JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration - RAS ON/OFF trial Phase 1/2 trial NCT06973564 Opened May 2025 4 US locations clinicaltrials.gov/study/NCT… AACR23: Preclinical investigation of orally bioavailable, potent KRASmulti inhibitor JAB-23425 aacrjournals.org/cancerres/a…
1
9
936
Proud of @vserpashigbie for leading the work at @UTMDAnderson on DPYD testing prior to 5-FU/capecitabine chemotherapy and institutional pharmacogenomics efforts. #ASCOQLTY26
2
21
636
The utterly hard-to-treat metastatic #CRC : #MSS #pMMR #BRAF #V600E #livermets , given #nivolumab #ICB #ICI #ICPI following #immunogenic short-course #oxaliplatin based chemo, resulting in durable #CR. The #METIMMOX study 🇳🇴
Top: At baseline. Bottom: At complete response (even the primary tumor!)

ALT Top: At baseline. Bottom: At complete response (even the primary tumor!)

1
1
2
534
Anne Hansen Ree Reports Four Accepted METIMMOX Abstracts for ESMO 2026 @anne_h_ree oncodaily.com/science/anne-h…
3
3
216
Load more